Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction
Launched by XUZHOU CENTRAL HOSPITAL · May 5, 2015
Trial Information
Current as of September 06, 2025
Unknown status
Keywords
ClinConnect Summary
Reperfusion injury might occur in patients with acute ST segment elevation myocardial infarction undergoing the primary percutaneous coronary intervention(P-PCI),characterized by myocardial stunning, reperfusion-induced arrhythmia, microvascular dysfunction and myocardial cellular apoptosis, etc.
Nicorandil is an antianginal agent with a dual mechanism of action: nitrate and K+ATP channel opener. The nitrate action causes vasodilation of systemic veins and epicardial coronary arteries, while the adenosine triphosphate (ATP)-sensitive potassium channel opener action causes vasodilation of p...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute ST Segment Elevation Myocardial Infarction (ASTEMI) defined as typical chest pain lasting \>30min within the previous 12 h, with a clear ST-segment elevation of \>0.1millivolt(mV) in ≥2 contiguous electrocardiographic leads, and the value of troponin I(TNI) above the maximum peak in the normal range.
- • Age20-80,All genders
- • The first myocardial infarction, and there is no history of PCI therapy and coronary artery bypass grafting
- • The infarct-related artery(IRA) is totally occlusive
- • Blood pressure is higher than 90/60 millimeters of mercury（mmHg）
- • The time from myocardial infarction onset to reach the hospital is less than 12 hs
- • Successful interventional treatment, the residual stenosis of IRA is less than 30% ,
- • TIMI flow grade 3
- Exclusion Criteria:
- • kidney dysfunction (creatinine \>2 mg/dl),
- • History of previous liver disease,
- • Cardiogenic shock,
- • History of myocardial infarction (MI)
- • History of coronary artery bypass grafting
- • History of allergic response to drugs
- • Right ventricular infarction
- • Severe hypovolemia
About Xuzhou Central Hospital
Xuzhou Central Hospital is a leading medical institution located in Xuzhou, China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a comprehensive teaching hospital, it is equipped with state-of-the-art facilities and a multidisciplinary team of specialists dedicated to providing high-quality patient care and conducting clinical trials. The hospital actively engages in research initiatives aimed at enhancing treatment modalities and improving patient outcomes, positioning itself as a pivotal contributor to the medical community both nationally and internationally. With a focus on ethical practices and patient safety, Xuzhou Central Hospital strives to foster advancements in medical knowledge and therapeutic interventions through rigorous clinical investigation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xuzhou, Jiangsu, China
Patients applied
Trial Officials
Institute of Cardiovascular Disease Xuzhou Central Hospital
Study Director
Southeast University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials